Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fbxo7 gets proactive with cyclin D/cdk6.

Heike Laman1

  • 1Division of Virology, Department of Pathology, University of Cambridge, Cambridge, UK. hl316@cam.ac.uk

Cell Cycle (Georgetown, Tex.)
|January 18, 2006
PubMed
Summary

Fbxo7 enhances cyclin D-cdk6 interactions, promoting cell cycle entry. This protein

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

rAAV Fbxo7 gene therapy rescues the progressive nigrostriatal pathology in a mouse model of juvenile parkinsonism.

Acta neuropathologica communications·2026
Same author

Retraction Notice to: A FBXO7/EYA2-SCF<sup>FBXW7</sup> axis promotes AXL-mediated maintenance of mesenchymal and immune evasion phenotypes of cancer cells.

Molecular cell·2024
Same author

Study of an FBXO7 patient mutation reveals Fbxo7 and PI31 co-regulate proteasomes and mitochondria.

The FEBS journal·2024
Same author

Editorial: E3 ubiquitin ligases: From structure to physiology to therapeutics, Volume II.

Frontiers in physiology·2022
Same author

Fbxo7 promotes Cdk6 activity to inhibit PFKP and glycolysis in T cells.

The Journal of cell biology·2022
Same author

A FBXO7/EYA2-SCF<sup>FBXW7</sup> axis promotes AXL-mediated maintenance of mesenchymal and immune evasion phenotypes of cancer cells.

Molecular cell·2022

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • D cyclins bind and activate cyclin-dependent kinases (CDKs) 2, 4, and 6.
  • Fbxo7 is identified as a selective enhancer of CDK6 activity.

Purpose of the Study:

  • To characterize the role of Fbxo7 in regulating CDK6 activity.
  • To investigate the potential oncogenic function of Fbxo7.

Main Methods:

  • Investigated Fbxo7's interaction with CDK6 and D cyclins.
  • Assessed the effect of Fbxo7 overexpression on cell cycle regulation.
  • Examined Fbxo7 expression in human cancers.

Main Results:

  • Fbxo7 directly facilitates CDK6 interaction with D cyclins, enhancing CDK6 activity.
  • Fbxo7 overexpression exhibits transforming activity in murine fibroblasts.
  • Fbxo7 is highly expressed in human cancers, indicating its potential as an oncogene.
  • Fbxo7 is part of an E3 ubiquitin ligase complex, suggesting a role in protein degradation and cell cycle control.

Conclusions:

  • Fbxo7 acts as a selective enhancer of CDK6 activity, promoting cell cycle entry.
  • Fbxo7's oncogenic potential and its role in coordinating ubiquitination with cell cycle progression warrant further investigation.

Related Experiment Videos